CrystalGenomics Applies for Early Termination of Domestic Phase 2 Trial for COVID-19 Treatment
[Asia Economy Reporter Myunghwan Lee] CrystalGenomics announced on the 1st that it has applied for early termination of the Phase 2 clinical trial plan evaluating the efficacy and safety of 'Camostat,' a COVID-19 treatment candidate.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Regarding the reason for early termination, CrystalGenomics explained, "Due to the global spread of Omicron subvariants and the expansion of vaccine prescriptions, the transition to endemic (periodic outbreak of infectious diseases) is rapidly progressing, making it difficult to recruit clinical trial patients," adding, "With the entry into the COVID endemic phase, regulatory authorities are also discontinuing 'fast-track' procedures such as emergency approvals."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
